Høydosebehandling med autolog stamcellestøtte ved lymfom i Norge 1987 - 2008
Tidsskrift for den Norske Laegeforening, ISSN: 0807-7096, Vol: 133, Issue: 16, Page: 1704-1709
2013
- 12Citations
- 4Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations12
- Citation Indexes12
- 12
- CrossRef10
- Captures4
- Readers4
Article Description
High-dose therapy with autologous stem cell support (HDT) has been a treatment option for lymphomas in Norway for 25 years. The purpose of the article was to describe the use of the therapy for lymphomas for the country as a whole and by health region, and to reveal the overall survival rate.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84887371867&origin=inward; http://dx.doi.org/10.4045/tidsskr.13.0243; http://www.ncbi.nlm.nih.gov/pubmed/24005706; https://tidsskriftet.no/2013/09/originalartikkel/hoydosebehandling-med-autolog-stamcellestotte-ved-lymfom-i-norge-1987-2008; https://dx.doi.org/10.4045/tidsskr.13.0243
Norwegian Medical Association
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know